Bulk CD34+ Cells from GCSF + PLX Mobilized Leukopaks CellsExpress

High recovery CD34+ hematopoietic stem and progenitor cells isolated from GCSF + PLX mobilized leukopaks. Bulk processing up to 2 x 10e10 TNC with ≥80% post thaw viability for advanced stem cell and gene therapy workflows.

Since our founding in 2010, CGT Global has pursued our mission to transform healthcare as we accelerate cell and gene therapy research and clinical trials, streamline the commercialization of new treatments, and map the last mile to patient access to these life-changing remedies.  By innovating each stage in the cycle; development, commercialization, and delivery, we reduce the overall cost of the care and multiply access points so that millions can receive cutting edge, life-saving gene and cell therapies.

CGT Global - Landing Page Desktop Prototype

Description

CD34+ hematopoietic stem and progenitor cells isolated from GCSF + PLX mobilized leukopaks are optimized for programs requiring enhanced stem cell mobilization and high recovery yields.

The combined mobilization strategy increases circulating CD34+ populations, enabling large scale isolation for demanding cell and gene therapy applications.

CellsExpress bulk CD34+ isolation from GCSF + PLX mobilized leukopaks is designed to protect yield from valuable collections while eliminating in house processing variability and isolation risk.

We process up to 2 x 10e10 total nucleated cells per mobilized leukopak and deliver cryopreserved CD34+ cells ready for immediate downstream use.

Key Features

• CD34+ cells isolated from GCSF + PLX mobilized leukopaks
• Up to 2 x 10e10 total nucleated cells processed
• High recovery stem and progenitor cell enrichment
• ≥80% post thaw viability
• High purity CD34+ isolation
• Cryopreserved and ready for immediate use
• Custom vial sizing available
• HLA typing and recallable donors available

Ideal Applications

• Hematopoietic stem cell therapy development
• Gene editing platforms and CRISPR workflows
• Stem cell expansion and differentiation research
• Advanced process development programs
• In vivo efficacy and safety studies
• Scalable CD34+ cell banking

For programs requiring maximum CD34+ yield from mobilized collections, GCSF + PLX mobilization provides enhanced recovery potential compared to single agent mobilization strategies.

CellsExpress ensures controlled, quality monitored bulk isolation so your team can focus on development, not processing logistics.

Additional information

Anticoagulant

Format

Grade

Species

Cell and Tissue Source

Disease State

Donor Attributes

Product Information Sheet

 

Mobilized Peripheral Blood

Selected publications demonstrating the use of mobilized peripheral blood and mobilized leukopak-derived CD34+ hematopoietic stem and progenitor cells in gene therapy, cell therapy, and transplantation workflows.


Hematopoietic reconstitution dynamics of mobilized peripheral blood-derived stem cells after gene therapy

Nature Communications · 2023

Mobilized peripheral blood-derived hematopoietic stem and progenitor cells were used for gene therapy, showing improved engraftment and recovery compared to traditional sources.

Mobilized Blood · HSPC · Gene Therapy


In vivo CRISPR gene editing in hematopoietic stem cells

Nature Biotechnology · 2022

Mobilized CD34+ hematopoietic stem cells were used in gene editing workflows to evaluate therapeutic genome engineering strategies.

CD34+ Cells · CRISPR · Gene Editing


Ex vivo expansion and functional characterization of hematopoietic stem cells

Stem Cell Research · 2023

Mobilized peripheral blood-derived hematopoietic stem cells were expanded ex vivo and evaluated for functional and therapeutic potential.

HSPC · Expansion · Stem Cell Biology


Optimized lentiviral production and transduction of primary human cells

Molecular Therapy Methods & Clinical Development · 2024

Mobilized CD34+ cells and primary immune cells were transduced using optimized viral production systems for gene and cell therapy applications.

CD34+ Cells · Viral Transduction


Improved workflows for gene modification in hematopoietic stem cells

Molecular Therapy Methods & Clinical Development · 2024

Mobilized hematopoietic stem cells were used to evaluate improved gene modification and cell engineering workflows.

Gene Editing · HSPC


Mobilized peripheral blood stem cells in transplantation and hematologic recovery

Blood · 2023

Mobilized peripheral blood stem cells were used in transplantation workflows to evaluate hematologic recovery and clinical outcomes.

Transplantation · Mobilized Blood